ArticleRSC advances2021
A novel route to size-controlled MIL-53(Fe) metal-organic frameworks for combined chemodynamic therapy and chemotherapy for cancer.
Article in RSC advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 55 citations in OpenAlex.
- Article
- Nanoencapsulation of Tomentosin-RichPharmaceutics · 2026Article
- Metal-organic framework impregnated sponge-based TENG as a binary input device for logic gate simulation and power plant control.Discover nano · 2025Article
- MOF enhances the sensitivity and selectivity of sorafenib as an anticancer drug against hepatocellular carcinoma and colorectal cancer in vitro.Scientific reports · 2025Article
- MIL-53 MOF on Sustainable Biomaterial for Antimicrobial Evaluation AgainstJournal of functional biomaterials · 2025Article
- An analytical review of the therapeutic application of recent trends in MIL-based delivery systems in cancer therapy.Mikrochimica acta · 2025Review
- Metal-organic frameworks as nanoplatforms for combination therapy in cancer treatment.Medical oncology (Northwood, London, England) · 2024Review
- Biomedical Metal-Organic Framework Materials: Perspectives and Challenges.Advanced functional materials · 2024Article
- Microwave-Responsive Metal-Organic Frameworks (MOFs) for Enhanced In Vitro Controlled Release of Doxorubicin.Nanomaterials (Basel, Switzerland) · 2024Article
- Advancing stroke therapy: the potential of MOF-based nanozymes in biomedical applications.Frontiers in bioengineering and biotechnology · 2024Review
- Fe-Based Metal Organic Frameworks (Fe-MOFs) for Bio-Related Applications.Pharmaceutics · 2023Review
- Synthesis of manganese-oxide and palladium nanoparticles co-decorated polypyrrole/graphene oxide (MnORSC advances · 2022Article
- Turn-on fluorescence determination of sulfide based on site-occupying modulation of MOF-copper nanocluster interaction.Mikrochimica acta · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metal-organic frameworks (MOFs), such as MIL-53(Fe), have considerable potential as drug carriers in cancer treatment due to their notable characteristics, including controllable particle sizes, high catalytic activity, biocompatibility and large porosity, and are widely used in a broad range of drugs. In this study, a new approach for the synthesis of MIL-53(Fe) nanocrystals with controlled sizes has been developed using a non-ionic surfactant PVP as the conditioning and stabilizing agent, respectively. During the nucleation of MIL-53(Fe), the PVP droplet, as a nano-reactor, controlled the growth of the crystal nucleus. The size and aspect ratio (length/width) of nanocrystals increased with an increase in PVP in the synthetic mixture. The MIL-53(Fe) nanocrystals showed a homogeneous morphology, with approximately 190 nm in length and 100 nm in width. MIL-53(Fe) not only was used to load the anticancer drug doxorubicin (DOX) but also generated hydroxyl radicals (˙OH)
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.